Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
David FitzGerald
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Concepts & Ideas
Physiology
Anatomy
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
69
Pastan, Ira
20
Kreitman, Robert
7
Waldmann, Thomas
5
McKee, Marian
5
Mrsny, Randall
4
Pastrana, Diana
4
Hassan, Raffit
4
Strickland, Dudley
3
Leppla, Stephen
3
Lorberboum-Galski, Haya
3
Brinkmann, Ulrich
3
Daugherty, AL
3
Wang, Qing-Cheng
2
Pirker, Robert
2
Mansfield, E
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of David FitzGerald (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Kreitman Robert J; Hassan Raffit; Fitzgerald David J; Pastan Ira
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5274-9.
-
2009: Sarnovsky Robert; Rea Jennifer; Makowski Matt; Hertle Ralf; Kelly Colleen; Antignani Antonella; Pastrana Diana V; Fitzgerald David J
Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.
The Journal of biological chemistry 2009;284(15):10243-53.
-
2009: Weldon John E; Xiang Laiman; Chertov Oleg; Margulies Inger; Kreitman Robert J; FitzGerald David J; Pastan Ira
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Blood 2009;113(16):3792-800.
-
2008: Du Xing; Beers Richard; Fitzgerald David J; Pastan Ira
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
Cancer research 2008;68(15):6300-5.
-
2008: Pastrana Diana V; Yun Cheol H; McKee Marian L; Fitzgerald David J
Mammalian cell expression of an active site mutant of Pseudomonas exotoxin disrupts LRP1 maturation.
Journal of biomedical science 2008;15(4):427-39.
-
2007: Pastan Ira; Hassan Raffit; FitzGerald David J; Kreitman Robert J
Immunotoxin treatment of cancer.
Annual review of medicine 2007;58():221-37.
-
2006: Onda Masanori; Nagata Satoshi; FitzGerald David J; Beers Richard; Fisher Robert J; Vincent James J; Lee Byungkook; Nakamura Michihiro; Hwang Jaulang; Kreitman Robert J; Hassan Raffit; Pastan Ira
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(12):8822-34.
-
2006: Pastan Ira; Hassan Raffit; Fitzgerald David J; Kreitman Robert J
Immunotoxin therapy of cancer.
Nature reviews. Cancer 2006;6(7):559-65.
-
2006: Pastrana Diana V; FitzGerald David J
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin.
Analytical biochemistry 2006;353(2):266-71.
-
2005: Pastrana Diana V; Hanson Alison J; Knisely Jane; Bu Guojun; Fitzgerald David J
LRP 1 B functions as a receptor for Pseudomonas exotoxin.
Biochimica et biophysica acta 2005;1741(3):234-9.
-
2004: FitzGerald David J; Kreitman Robert; Wilson Wyndham; Squires David; Pastan Ira
Recombinant immunotoxins for treating cancer.
International journal of medical microbiology : IJMM 2004;293(7-8):577-82.
-
2002: Mrsny Randall J; Daugherty Ann L; McKee Marian L; FitzGerald David J
Bacterial toxins as tools for mucosal vaccination.
Drug discovery today 2002;7(4):247-58.
-
2001: Hertle R; Mrsny R; Fitzgerald D J
Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.
Infection and immunity 2001;69(11):6962-9.
-
2001: Kreitman R J; Wilson W H; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald D J; Pastan I
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
The New England journal of medicine 2001;345(4):241-7.
-
2000: Kreitman R J; Margulies I; Stetler-Stevenson M; Wang Q C; FitzGerald D J; Pastan I
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1476-87.
-
2000: Daugherty A L; McKee M L; FitzGerald D J; Mrsny R J
Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node.
Journal of controlled release : official journal of the Controlled Release Society 2000;65(1-2):297-302.
-
1999: McKee M L; FitzGerald D J
Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story.
Biochemistry 1999;38(50):16507-13.
-
1999: Mrsny R J; Daugherty A L; Fryling C M; FitzGerald D J
Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.
Vaccine 1999;17(11-12):1425-33.
-
1999: Kreitman R J; Wang Q C; FitzGerald D J; Pastan I
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
International journal of cancer. Journal international du cancer 1999;81(1):148-55.
-
1998: FitzGerald D J; Fryling C M; McKee M L; Vennari J C; Wrin T; Cromwell M E; Daugherty A L; Mrsny R J
Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.
The Journal of biological chemistry 1998;273(16):9951-8.
-
1997: Mansfield E; Amlot P; Pastan I; FitzGerald D J
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Blood 1997;90(5):2020-6.
-
1997: Mansfield E; Chiron M F; Amlot P; Pastan I; FitzGerald D J
Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells.
Biochemical Society transactions 1997;25(2):709-14.
-
1996: Chiron M F; Ogata M; FitzGerald D J
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.
Molecular microbiology 1996;22(4):769-78.
-
1996: Mansfield E; Pastan I; FitzGerald D J
Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
Bioconjugate chemistry 1996;7(5):557-63.
-
1996: Zdanovsky A G; Zdanovskaia M V; Strickland D; FitzGerald D J
Ligand-toxin hybrids directed to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than native Pseudomonas exotoxin.
The Journal of biological chemistry 1996;271(11):6122-8.
-
1996: Gu M; Gordon V M; Fitzgerald D J; Leppla S H
Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells.
Infection and immunity 1996;64(2):524-7.
-
1995: FitzGerald D J; Fryling C M; Zdanovsky A; Saelinger C B; Kounnas M; Winkles J A; Strickland D; Leppla S
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
The Journal of cell biology 1995;129(6):1533-41.
-
1995: Pastan I H; Pai L H; Brinkmann U; Fitzgerald D J
Recombinant toxins: new therapeutic agents for cancer.
Annals of the New York Academy of Sciences 1995;758():345-54.
-
1994: Fitzgerald D J; Fryling C M; Zdanovsky A; Saelinger C B; Kounnas M; Strickland D K; Leppla S
Selection of Pseudomonas exotoxin-resistant cells with altered expression of alpha 2MR/LRP.
Annals of the New York Academy of Sciences 1994;737():138-44.
-
1994: Chiron M F; Fryling C M; FitzGerald D J
Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver.
The Journal of biological chemistry 1994;269(27):18167-76.
-
1994: Kreitman R J; Bailon P; Chaudhary V K; FitzGerald D J; Pastan I
Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Blood 1994;83(2):426-34.
-
1993: Zdanovsky A G; Chiron M; Pastan I; FitzGerald D J
Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step.
The Journal of biological chemistry 1993;268(29):21791-9.
-
1993: Wang Q C; Pai L H; Debinski W; FitzGerald D J; Pastan I
Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.
Cancer research 1993;53(19):4588-94.
-
1993: Theuer C P; FitzGerald D J; Pastan I
A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
The Journal of urology 1993;149(6):1626-32.
-
1993: Kreitman R J; Chaudhary V K; Waldmann T A; Hanchard B; Cranston B; FitzGerald D J; Pastan I
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(4):553-62.
-
1993: Kreitman R J; Batra J K; Seetharam S; Chaudhary V K; FitzGerald D J; Pastan I
Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Bioconjugate chemistry 1993;4(2):112-20.
-
1993: Kreitman R J; Hansen H J; Jones A L; FitzGerald D J; Goldenberg D M; Pastan I
Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Cancer research 1993;53(4):819-25.
-
1993: Theuer C P; Kreitman R J; FitzGerald D J; Pastan I
Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Cancer research 1993;53(2):340-7.
-
1992: Ogata M; Fryling C M; Pastan I; FitzGerald D J
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.
The Journal of biological chemistry 1992;267(35):25396-401.
-
1992: FitzGerald D J; Pastan I
Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
Biochemical Society transactions 1992;20(4):731-4.
-
1992: Kreitman R J; Chaudhary V K; Kozak R W; FitzGerald D J; Waldman T A; Pastan I
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Blood 1992;80(9):2344-52.
-
1992: Kreitman R J; Schneider W P; Queen C; Tsudo M; Fitzgerald D J; Waldmann T A; Pastan I
Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(8):2810-5.
-
1992: Kounnas M Z; Morris R E; Thompson M R; FitzGerald D J; Strickland D K; Saelinger C B
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A.
The Journal of biological chemistry 1992;267(18):12420-3.
-
1992: Pai L H; Batra J K; FitzGerald D J; Willingham M C; Pastan I
Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Cancer research 1992;52(11):3189-93.
-
1992: Prior T I; FitzGerald D J; Pastan I
Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol.
Biochemistry 1992;31(14):3555-9.
-
1992: Kreitman R J; Siegall C B; FitzGerald D J; Epstein J; Barlogie B; Pastan I
Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
Blood 1992;79(7):1775-80.
-
1992: Brinkmann U; Pai L H; FitzGerald D J; Pastan I
Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(7):3065-9.
-
1992: Kreitman R J; Siegall C B; Chaudhary V K; FitzGerald D J; Pastan I
Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.
Bioconjugate chemistry 1992;3(1):63-8.
-
1992: Kreitman R J; Chaudhary V K; Siegall C B; FitzGerald D J; Pastan I
Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand.
Bioconjugate chemistry 1992;3(1):58-62.
-
1992: Pastan I; Chaudhary V; FitzGerald D J
Recombinant toxins as novel therapeutic agents.
Annual review of biochemistry 1992;61():331-54.
-
1991: Chaudhary V K; FitzGerald D J; Pastan I
A proper amino terminus of diphtheria toxin is important for cytotoxicity.
Biochemical and biophysical research communications 1991;180(2):545-51.
-
1991: Brinkmann U; Pai L H; FitzGerald D J; Willingham M; Pastan I
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(19):8616-20.
-
1991: Siegall C B; Epstein S; Speir E; Hla T; Forough R; Maciag T; Fitzgerald D J; Pastan I
Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1991;5(13):2843-9.
-
1991: Siegall C B; Ogata M; Pastan I; FitzGerald D J
Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation.
Biochemistry 1991;30(29):7154-9.
-
1991: Pai L H; Gallo M G; FitzGerald D J; Pastan I
Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
Cancer research 1991;51(11):2808-12.
-
1991: Siegall C B; Kreitman R J; FitzGerald D J; Pastan I
Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Cancer research 1991;51(11):2831-6.
-
1991: Pai L H; Batra J K; FitzGerald D J; Willingham M C; Pastan I
Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3358-62.
-
1991: Batra J K; Fitzgerald D J; Chaudhary V K; Pastan I
Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
Molecular and cellular biology 1991;11(4):2200-5.
-
1991: Prior T I; FitzGerald D J; Pastan I
Barnase toxin: a new chimeric toxin composed of pseudomonas exotoxin A and barnase.
Cell 1991;64(5):1017-23.
-
1991: Prior T I; Helman L J; FitzGerald D J; Pastan I
Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin.
Cancer research 1991;51(1):174-80.
-
1990: Siegall C B; Schwab G; Nordan R P; FitzGerald D J; Pastan I
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Cancer research 1990;50(24):7786-8.
-
1990: Pai L H; FitzGerald D J; Tepper M; Schacter B; Spitalny G; Pastan I
Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.
Cancer research 1990;50(24):7750-3.
-
1990: Chaudhary V K; Gallo M G; FitzGerald D J; Pastan I
A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(23):9491-4.
-
1990: Kreitman R J; Chaudhary V K; Waldmann T; Willingham M C; FitzGerald D J; Pastan I
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(21):8291-5.
-
1990: Ogata M; Chaudhary V K; Pastan I; FitzGerald D J
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.
The Journal of biological chemistry 1990;265(33):20678-85.
-
1990: Ashorn P; Moss B; Weinstein J N; Chaudhary V K; FitzGerald D J; Pastan I; Berger E A
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8889-93.
-
1990: Kozak R W; Lorberboum-Galski H; Jones L; Puri R K; Willingham M C; Malek T; Fitzgerald D J; Waldmann T A; Pastan I
IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(8):2766-71.
-
1990: Siegall C B; FitzGerald D J; Pastan I
Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules.
Seminars in cancer biology 1990;1(5):345-50.
-
1990: Siegall C B; FitzGerald D J; Pastan I
Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels.
The Journal of biological chemistry 1990;265(27):16318-23.
-
1990: Lorberboum-Galski H; Garsia R J; Gately M; Brown P S; Clark R E; Waldmann T A; Chaudhary V K; FitzGerald D J; Pastan I
IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.
The Journal of biological chemistry 1990;265(27):16311-7.
-
1990: Siegall C B; Nordan R P; FitzGerald D J; Pastan I
Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells.
Molecular and cellular biology 1990;10(6):2443-7.
-
1990: Chaudhary V K; Batra J K; Gallo M G; Willingham M C; FitzGerald D J; Pastan I
A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(3):1066-70.
-
1990: Siegall C B; FitzGerald D J; Pastan I
Selective killing of IL6 receptor bearing myeloma cells using recombinant IL6-Pseudomonas toxin.
Current topics in microbiology and immunology 1990;166():63-9.
-
1989: Batra J K; Jinno Y; Chaudhary V K; Kondo T; Willingham M C; FitzGerald D J; Pastan I
Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(21):8545-9.
-
1989: Pirker R; FitzGerald D J; Raschack M; Frank Z; Willingham M C; Pastan I
Enhancement of the activity of immunotoxins by analogues of verapamil.
Cancer research 1989;49(17):4791-5.
-
1989: Siegall C B; Chaudhary V K; FitzGerald D J; Pastan I
Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin.
The Journal of biological chemistry 1989;264(24):14256-61.
-
1989: Ogata M; Chaudhary V K; FitzGerald D J; Pastan I
Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(11):4215-9.
-
1989: Chaudhary V K; Queen C; Junghans R P; Waldmann T A; FitzGerald D J; Pastan I
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.
Nature 1989;339(6223):394-7.
-
1989: Lorberboum-Galski H; Barrett L V; Kirkman R L; Ogata M; Willingham M C; FitzGerald D J; Pastan I
Cardiac allograft survival in mice treated with IL-2-PE40.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):1008-12.
-
1988: Siegall C B; Chaudhary V K; FitzGerald D J; Pastan I
Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(24):9738-42.
-
1988: Lorberboum-Galski H; Kozak R W; Waldmann T A; Bailon P; FitzGerald D J; Pastan I
Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor.
The Journal of biological chemistry 1988;263(35):18650-6.
-
1988: Jinno Y; Chaudhary V K; Kondo T; Adhya S; FitzGerald D J; Pastan I
Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity.
The Journal of biological chemistry 1988;263(26):13203-7.
-
1988: Chaudhary V K; Mizukami T; Fuerst T R; FitzGerald D J; Moss B; Pastan I; Berger E A
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
Nature 1988;335(6188):369-72.
-
1988: Gallo M G; Chaudhary V K; Fitzgerald D J; Willingham M C; Pastan I
Cloning and expression of the H chain V region of antibody OVB3 that reacts with human ovarian cancer.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(3):1034-40.
-
1988: Pirker R; FitzGerald D J; Willingham M C; Pastan I
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Cancer research 1988;48(14):3919-23.
-
1983: Willingham M C; Haigler H T; Fitzgerald D J; Gallo M G; Rutherford A V; Pastan I H
The morphologic pathway of binding and internalization of epidermal growth factor in cultured cells. Studies on A431, KB, and 3T3 cells, using multiple methods of labelling.
Experimental cell research 1983;146(1):163-75.
Sign-in to see more
